

EXTRAORDINARY INFORMATION

On the result of the voluntary public purchase offer of the Servier Group

Egis Pharmaceuticals PLC hereby discloses the enclosed notification regarding the result of the voluntary public purchase offer of Arts et Techniques du Progrès (Offeror), a fully owned subsidiary of the Servier Group, received from the Offeror.


Budapest, November 7, 2013

Egis Pharmaceuticals PLC

**ANNOUNCEMENT OF ARTS ET TECHNIQUES DU PROGRÈS AND KBC SECURITIES
HUNGARIAN BRANCH OFFICE**

Based on the obligation set out in section 76 of the Capital Markets Act, **Arts et Techniques du Progrès** (registered seat : 25 rue Eugène Vignat, 45000 Orléans, France; company registry number: 582 057 600; the "**Offeror**") and **KBC Securities Hungarian Branch Office** (registered seat: 1095 Budapest, Lechner Ödön fasor 10., registration number: 01-17-000381; the "**Tender Agent**") hereby announce in relation to the voluntary public purchase offer made by the Offeror to all shareholders of **Egis Pharmaceuticals Public Limited Company** (registered seat: 1106 Budapest, Keresztúri út 30-38. Hungary, company registry number: 01-10-041762; "**Egis Plc**") with respect to each voting registered ordinary share of Egis Plc. (the "**Offer**") that within the acceptance period (i.e. from 2 October 2013 to 5 November 2013) the total number of shares in relation to which the Offer was validly accepted is 3,543,617 and the respective ownership ratio in Egis Plc. reached by the Offeror (including the shares already owned by the Offeror before the Offer) is 96.43%.

Dated, Budapest, 7 November 2013.



Arts et Techniques du Progrès

represented by:

dr. Ákos Kovách
based on a power of attorney



KBC Securities Hungarian Branch

represented by:

Eddy D'Hertoge
Chief Executive Officer

Ádám Hegyi
Corporate Finance
Director